A thrombus in the venous reservoir while using bivalirudin in a patient with heparin-induced thrombocytopenia undergoing heart transplantation

Anesthesia and Analgesia

Volumn 111, Issue 3, 2010, Pages 609-612

  Wong, Jim K ^a   Tian, Ying ^a   Shuttleworth, Paul ^b   Caffarelli, Anthony D ^b   Reitz, Bruce A ^b   Mora Mangano, Christina T ^a  

^a Department of Anesthesia   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AMINOCAPROIC ACID; DOPAMINE; FRESH FROZEN PLASMA; HEPARIN; HEPARIN PLATELET FACTOR 4 ANTIBODY; HIRULOG; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBIN; HIRUDIN DERIVATIVE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

ADULT; ANAMNESIS; ANTIBODY DETECTION; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; CARDIOVASCULAR EQUIPMENT; CASE REPORT; CLINICAL FEATURE; CONGESTIVE CARDIOMYOPATHY; CONTINUOUS INFUSION; DISEASE COURSE; HEART FAILURE; HEART TRANSPLANTATION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBUS; VENOUS RESERVOIR; AORTA BALLOON; BLOOD; CHEMICALLY INDUCED DISORDER; FIBRINOLYSIS; METHODOLOGY; MIDDLE AGED; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT FAILURE;

ANTICOAGULANTS; ANTITHROMBINS; CARDIOMYOPATHY, DILATED; FIBRINOLYSIS; HEART TRANSPLANTATION; HEPARIN; HIRUDINS; HUMANS; INTRA-AORTIC BALLOON PUMPING; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT FAILURE; WHOLE BLOOD COAGULATION TIME;

EID: 77956409214     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ANE.0b013e3181e9ead3     Document Type: Article

References (33)

1. Koster A, Dyke CM, Aldea G, Smeddira NG, McCarthy HL II, Aronson S, Hetzer R, Avery E, Spiess B, Lincoff AM. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg 2007;83:572-7
2. Dyke CM, Smedira NG, Koster A, Aronson S, McCarthy HL II, Kirshner R, Lincoff AM, Spiess BD. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg 2006;131: 533-9
3. Warkentin TE, Greinacher A, Koster A, Lincoff M. Treatment and prevention of heparin-induced thrombocytopenia. Chest 2008;133:340S-80S
4. Watson HG, Keeling DM. The management of heparininduced thrombocytopenia [Correspondence]. Br J of Haematology 2006;135:264-75
5. Robson R. The use of bivalirudin in patients with renal impairment. J Invasive Cardiol 2000;12(Suppl F):33F-6F
6. Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med 2005;353:1028-40
7. Koster A, Chew D, Grundel M, Hausmann H, Grauhan O, Kuppe H, Spiess BD. An assessment of different filter systems for extra corporeal elimination of bivalirudin: an in vitro study. Anesth Analg 2003;96:1316-9
8. Koster A, Buz S, Krabatsch T, Dehmel F, Kuppe H, Hetzer R, Aronson S, Dyke CM. Effect of modified ultrafiltration on bivalirudin elimination and postoperative blood loss after on-pump coronary artery bypass grafting: assessment of different filtration strategies. J Card Surg 2008;23:655-88
9. Mann MJ, Tseng E, Ratcliffe M, Strattman G, DeSilva A, Demarco T, Achorn N, Moskalik W, Hoopes C. Use of bivalirudin, a direct thrombin inhibitor, and its reversal with modified ultrafiltration during heart transplantation in a patient with heparin-induced thrombocytopenia. J Heart Lung Transplant 2005;24:222-5
10. Koster A, Merkle F, Hansen R, Loebe M, Kuppe H, Hetzer R, Crystal GJ, Mertzlufft F. Elimination of recombinant hirudin by modified ultrafiltration during simulated cardiopulmonary bypass: assessment of different filter systems. Anesth Analg 2000;91:265-9
11. Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of Bivalirudin Angioplasty Study. Am Heart J 2001;142:952-9
12. Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, Maraganore J, Deutsch E, Adelman B. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med 1995;333:764-9
13. Bittl JA. Comparative safety profiles of hirulog and heparin in patients undergoing coronary angioplasty. The Hirulog Angioplasty Study Investigators. Am Heart J 1995;130:658-65
14. Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohan EA, Betrui A, Desmet W, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004;292:696-703
15. Lincoff AM, Kleiman NS, Kottke-Marchant K, Maierson ES, Maresh K, Wolski KE, Topol EJ. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J 2002;143:847-53
16. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Harmon M, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, Ohman EM. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355:2206-16
17. Dyke CM, Koster A, Veale JJ, Maier GW, McNiff T, Levy JH. Preemptive use of bivalirudin for urgent on-pump coronary artery bypass grafting in patients with potential heparininduced thrombocytopenia. Ann Thorac Surg 2005;80:299-303
18. Reiss FC. Anticoagulation management and cardiac surgery in patients with heparin-induced thrombocytopenia. Semin Thorac Cardiovasc Surg 2005;17:85-96
19. Murphy GS, Marymont JH. Alternative anticoagulation management strategies for the patient with heparin-induced thrombocytopenia undergoing cardiac surgery. J Cardiothorac Vasc Anesth 2007;21:113-26
20. Clayton SB, Acsell JR, Crumbley AJ III, Uber WE. Cardiopulmonary bypass with bivalirudin in type II heparin-induced thrombocytopenia. Ann Thorac Surg 2004;78:2167-9
21. Levy JH, Winkler AM. Heparin-induced thrombocytopenia and cardiac surgery. Curr Opin Anaesth 2010;23:74-9
22. Wippermann J, Albes JM, Hartrumpf M, Kaluza M, Vollandt R, Bruhin R, Wahlers T. Comparison of minimally invasive closed circuit extracorporeal circulation with conventional cardiopulmonary bypass and with off-pump technique in CABG patients: selected parameters of coagulation and inflammatory system. Eur J Cardiothorac Surg 2005;28:127-32
23. Potzsch B, Hund S, Madlener K, Unkrig C, Muller-Berghaus G. Monitoring of recombinant hiurdin: assessment of a plasmabased ecarin clotting time assay. Thromb Res 1997;86:373-83
24. Potzsch B, Madlener K, Seelig C, Riess CF, Greinacher A, Muller-Berghaus G. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass-assessment of the whole blood ecarin clotting time. Thromb Haemost 1997;77:920-5
25. Nowak G, Bucha E. Quantitative determination of hirudin in blood and body fluids. Semin Thromb Hemost 1996;22:197-202
26. Hafner G, Roser M, Nauck M. Methods for the monitoring of direct thrombin inhibitors. Semin Thromb Hemost 2002; 28:425-30
27. Despotis GJ, Hogue CW, Saleem R, Bigham M, Skubas N, Apostolidou I, Qayum A, Joist JH. The relationship between hirudin and activated clotting time: implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery. Anesth Analg 2001;93:28-32
28. Cho L, Kottke-Marchant K, Lincoff AM, Roffi M, Reginelli JP, Kaldus T, Moliterno DJ. Correlation of point-of-care ecarin clotting time versus activated clotting time with bivalirudin concentrations. Am J Cardiol 2003;91:1110-3
29. Koster A, Chew D, Grundel M, Bauer M, Kuppe H, Spiess BD. Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypass. Anesth Analg 2003;96:383-6
30. Warkentin TE, Sheppard J, Moore JC, Moore KM, Sigouin CS, Kelton JG. Laboratory testing for antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med 2005;146:341-6
31. Warkentin TE, Sheppard J, Moore JC, Sigouin CS, Kelton JG. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost 2008;6:1304-12
32. Zwicker JI, Uhl L, Huang WY, Shaz BH, Bauer KA. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2004; 2:2133-7
33. Nielsen VG, Steenwyk BL, Gurley WQ, Pereira SJ, Lell WA, Kirklin JK. Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as heparin-activated antithrombin in vitro. J Heart Lung Transplant 2006;25:653-63